In this context, MKC8866 could potentially provide a valuable addition to the spectrum of PCa therapies, especially in tumors that display elevated IRE1α-XBP1s activity upon ADT or chemotherapy. The gene discussed is ERN1; the disease is posterior cortical atrophy.